MX2021009254A - Metodos y composiciones para el desarrollo de productos de factores de crecimiento y exosomas objetivo especificos. - Google Patents
Metodos y composiciones para el desarrollo de productos de factores de crecimiento y exosomas objetivo especificos.Info
- Publication number
- MX2021009254A MX2021009254A MX2021009254A MX2021009254A MX2021009254A MX 2021009254 A MX2021009254 A MX 2021009254A MX 2021009254 A MX2021009254 A MX 2021009254A MX 2021009254 A MX2021009254 A MX 2021009254A MX 2021009254 A MX2021009254 A MX 2021009254A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- development
- growth factor
- specific targeted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/985—Skin or skin outgrowth, e.g. hair, nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0666—Mesenchymal stem cells from hair follicles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/124—Animal traits, i.e. production traits, including athletic performance or the like
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Birds (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798908P | 2019-01-30 | 2019-01-30 | |
| PCT/US2020/015982 WO2020160342A1 (en) | 2019-01-30 | 2020-01-30 | Methods and compositions for developing target specific exosome and growth factor products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009254A true MX2021009254A (es) | 2021-09-28 |
Family
ID=71842346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009254A MX2021009254A (es) | 2019-01-30 | 2020-01-30 | Metodos y composiciones para el desarrollo de productos de factores de crecimiento y exosomas objetivo especificos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220136053A1 (https=) |
| EP (1) | EP3917489A4 (https=) |
| JP (2) | JP2022535178A (https=) |
| KR (1) | KR20210121183A (https=) |
| AU (1) | AU2020214832A1 (https=) |
| BR (1) | BR112021014994A2 (https=) |
| CA (1) | CA3128050A1 (https=) |
| IL (1) | IL285228A (https=) |
| JO (1) | JOP20210202A1 (https=) |
| MX (1) | MX2021009254A (https=) |
| SG (1) | SG11202108129SA (https=) |
| WO (1) | WO2020160342A1 (https=) |
| ZA (1) | ZA202105483B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021526556A (ja) | 2018-05-30 | 2021-10-07 | ダイレクト バイオロジクス エルエルシー | 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法 |
| BR112021015549A2 (pt) | 2019-02-07 | 2021-10-26 | Direct Biologics Llc | Método para tratar osteoartrite com uma combinação de exossomos de células tronco mesenquimais, células tronco mesenquimais sinoviais e andaimes |
| CA3146433A1 (en) | 2019-07-18 | 2021-01-21 | Direct Biologics Llc | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use |
| US12590310B2 (en) | 2020-04-22 | 2026-03-31 | Direct Biologics, Llc | Methods and compositions for treating inflammatory conditions associated with infectious disease |
| JP2023180556A (ja) * | 2022-06-09 | 2023-12-21 | 日本メナード化粧品株式会社 | 薄毛の遺伝的素因の判定方法 |
| WO2024233684A2 (en) * | 2023-05-08 | 2024-11-14 | Vitti Labs | Methods of treating ovarian conditions and diseases |
| US12502407B2 (en) | 2024-04-25 | 2025-12-23 | Direct Biologics, Llc | Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles |
| CN118516305B (zh) * | 2024-07-22 | 2024-11-26 | 深圳大学 | 力学信号调控下的外泌体制备方法、外泌体及其在骨、软骨再生修复领域的应用 |
| CN120899659A (zh) * | 2025-08-06 | 2025-11-07 | 河北医科大学第三医院 | 一种过表达cap基因和lgr5基因的外泌体在制备治疗软骨炎症药物中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090177487A1 (en) * | 2008-01-07 | 2009-07-09 | Tera Eerkes | Methods for Assessing Genetic Compatibility |
| CN102014934B (zh) * | 2008-02-22 | 2014-08-20 | 新加坡科技研究局 | 间充质干细胞颗粒 |
| ES2746554T3 (es) * | 2010-11-02 | 2020-03-06 | Univ Columbia | Métodos para tratar los trastornos de pérdida de cabello |
| US20130129688A1 (en) * | 2011-11-09 | 2013-05-23 | Allocure, Inc. | Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same |
| CA2866563A1 (en) * | 2012-03-07 | 2013-09-12 | Fibrocell Technologies, Inc. | Topical dermal formulations and methods of personalized treatment of skin |
| EP3270984A4 (en) * | 2015-03-16 | 2019-04-17 | Duncan Ross | TREATMENT METHOD WITH MEMBRANE-INCLUDED VESICLE |
| AU2016261358B2 (en) * | 2015-05-11 | 2021-09-16 | Editas Medicine, Inc. | Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells |
| MX2019005127A (es) * | 2016-11-03 | 2019-09-26 | Exostem Biotec Ltd | Poblaciones y productos de células madre mesenquimales y sus usos. |
| US10987381B2 (en) * | 2017-01-27 | 2021-04-27 | Neil Riordan | Mesenchymal stem cells with enhanced efficacy in treatment of autoimmunity particularly rheumatoid arthritis |
| WO2018162696A1 (en) * | 2017-03-10 | 2018-09-13 | Institut Pasteur | Common genetic variations at the tcra-tcrd locus control thymic function in humans |
| JP2021526556A (ja) * | 2018-05-30 | 2021-10-07 | ダイレクト バイオロジクス エルエルシー | 成長因子および細胞外小胞を凍結または粉状にした、間葉系幹細胞（ｍｓｃ）の調製物を含む助剤、ならびにその使用方法 |
| KR20210121039A (ko) * | 2018-12-26 | 2021-10-07 | 다이렉트 바이오로직스 엘엘씨 | 피부 및 모발 장애를 치료하기 위한 방법 및 조성물 |
-
2020
- 2020-01-30 AU AU2020214832A patent/AU2020214832A1/en not_active Abandoned
- 2020-01-30 SG SG11202108129SA patent/SG11202108129SA/en unknown
- 2020-01-30 WO PCT/US2020/015982 patent/WO2020160342A1/en not_active Ceased
- 2020-01-30 CA CA3128050A patent/CA3128050A1/en active Pending
- 2020-01-30 JP JP2021544344A patent/JP2022535178A/ja active Pending
- 2020-01-30 BR BR112021014994-5A patent/BR112021014994A2/pt not_active Application Discontinuation
- 2020-01-30 KR KR1020217027591A patent/KR20210121183A/ko not_active Withdrawn
- 2020-01-30 JO JOP/2021/0202A patent/JOP20210202A1/ar unknown
- 2020-01-30 MX MX2021009254A patent/MX2021009254A/es unknown
- 2020-01-30 EP EP20748749.7A patent/EP3917489A4/en active Pending
- 2020-01-30 US US17/427,192 patent/US20220136053A1/en active Pending
-
2021
- 2021-07-29 IL IL285228A patent/IL285228A/en unknown
- 2021-08-02 ZA ZA2021/05483A patent/ZA202105483B/en unknown
-
2024
- 2024-11-20 JP JP2024202674A patent/JP2025037913A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210121183A (ko) | 2021-10-07 |
| SG11202108129SA (en) | 2021-08-30 |
| BR112021014994A2 (pt) | 2021-10-05 |
| JP2022535178A (ja) | 2022-08-05 |
| EP3917489A1 (en) | 2021-12-08 |
| CA3128050A1 (en) | 2020-08-06 |
| US20220136053A1 (en) | 2022-05-05 |
| JP2025037913A (ja) | 2025-03-18 |
| IL285228A (en) | 2021-09-30 |
| ZA202105483B (en) | 2022-07-27 |
| JOP20210202A1 (ar) | 2023-01-30 |
| WO2020160342A1 (en) | 2020-08-06 |
| AU2020214832A1 (en) | 2021-08-19 |
| EP3917489A4 (en) | 2022-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009254A (es) | Metodos y composiciones para el desarrollo de productos de factores de crecimiento y exosomas objetivo especificos. | |
| UY38701A (es) | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas | |
| MX2022003466A (es) | Interrupción de los tejidos tumorales al dirigir la proteína de activación de fibroblastos (fap). | |
| MX2020012495A (es) | Moleculas de union contra bcma y usos de las mismas. | |
| AR119746A1 (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
| MX379235B (es) | Compuestos y sus usos para modular la hemoglobina. | |
| BR112021019411A2 (pt) | Métodos para a produção de células car-nk e uso das mesmas | |
| UY34262A (es) | Hemifumarato de tenofovir alafenamida, sus composiciones, método de preparación, métodos para tratar infecciones virales y su uso para preparar medi camentos | |
| EA201590085A1 (ru) | Антитела анти-egfr и их применение | |
| MX350861B (es) | Anticuerpos frente al receptor del factor de crecimiento epidérmico (egfr) y usos de éstos. | |
| BR112022004972A2 (pt) | Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso | |
| BR112017007673A2 (pt) | modelagem corporal | |
| MX2016002574A (es) | Nuevos moduladores del homologo 6 (sez6) y metodos de uso. | |
| MX2021011608A (es) | Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines. | |
| CO2023013500A2 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| PE20160519A1 (es) | Compuestos de tetrahidrocarbozol y carbozol carboxamida sustituidos utiles como inhibidores de cinasa | |
| MX2020009522A (es) | Anticuerpos anti-folato del receptor 1 y usos de los mismos. | |
| MX2023009874A (es) | Anticuerpos anti-psma y estructuras car-t. | |
| AR101735A1 (es) | Anticuerpo terapéutico anti-bdnf (factor neurotrófico derivado del cerebro) | |
| MX2021012335A (es) | Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. | |
| CL2023003073A1 (es) | Anticuerpos anti-cd20 y estructuras car-t | |
| CO2023015859A2 (es) | Anticuerpos para tratar alfa-sinucleinopatías | |
| BR112012015653A2 (pt) | composições para formação de películas possuindo um desejado grau de obscurecimento e métodos para a sua produção e utilização | |
| MX2021015045A (es) | Construcciones de unión biespecíficas. |